These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 20956992)

  • 21. Achievement of renal anemia KDIGO targets by two different clinical strategies - a European hemodialysis multicenter analysis.
    Drozdz M; Weigert A; Silva F; Frazão J; Alsuwaida A; Krishnan M; Kleophas W; Brzosko S; Johansson FK; Jacobson SH
    BMC Nephrol; 2019 Jan; 20(1):5. PubMed ID: 30616548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
    Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
    Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of renal anemia with iron in hemodialysis patients in General Hospital Bjelovar].
    Lovcić V; Vujić J; Basić-Jukić N; Janković RI; Kurtović I; Dzapo M; Lovcić P
    Acta Med Croatica; 2011 Oct; 65 Suppl 3():45-8. PubMed ID: 23120815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents.
    van der Weerd NC; Grooteman MP; Bots ML; van den Dorpel MA; den Hoedt CH; Mazairac AH; Nubé MJ; Penne EL; Gaillard CA; Wetzels JF; Wiegerinck ET; Swinkels DW; Blankestijn PJ; Ter Wee PM;
    PLoS One; 2012; 7(7):e39783. PubMed ID: 22808058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iron therapy for renal anemia: how much needed, how much harmful?
    Hörl WH
    Pediatr Nephrol; 2007 Apr; 22(4):480-9. PubMed ID: 17206511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients.
    Sepandj F; Jindal K; West M; Hirsch D
    Nephrol Dial Transplant; 1996 Feb; 11(2):319-22. PubMed ID: 8671786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comprehensive vision for intravenous iron therapy.
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. When should iron supplementation in dialysis patients be avoided, minimized or withdrawn?
    Rostoker G
    Semin Dial; 2019 Jan; 32(1):22-29. PubMed ID: 29956370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hyporesponsiveness to erythropoietin therapy in hemodialyzed patients: potential role of prohepcidin, hepcidin, and inflammation.
    Malyszko J; Malyszko JS; Mysliwiec M
    Ren Fail; 2009; 31(7):544-8. PubMed ID: 19839848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
    Pergola PE; Devalaraja M; Fishbane S; Chonchol M; Mathur VS; Smith MT; Lo L; Herzog K; Kakkar R; Davidson MH
    J Am Soc Nephrol; 2021 Jan; 32(1):211-222. PubMed ID: 33272965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenge of effectively using erythropoiesis-stimulating agents and intravenous iron.
    Kapoian T
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S21-8. PubMed ID: 19010258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia.
    Majoni SW; Ellis JA; Hall H; Abeyaratne A; Lawton PD
    Hemodial Int; 2014 Oct; 18(4):740-50. PubMed ID: 24766376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepcidin for clinicians.
    Young B; Zaritsky J
    Clin J Am Soc Nephrol; 2009 Aug; 4(8):1384-7. PubMed ID: 19556376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sodium ferric gluconate complex therapy in anemic children on hemodialysis.
    Warady BA; Zobrist RH; Wu J; Finan E;
    Pediatr Nephrol; 2005 Sep; 20(9):1320-7. PubMed ID: 15971073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous versus oral iron for treatment of iron deficiency in non-hemodialysis-dependent patients with chronic kidney disease.
    Liles AM
    Am J Health Syst Pharm; 2012 Jul; 69(14):1206-11. PubMed ID: 22761074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients.
    Kaskel FJ
    Nat Clin Pract Nephrol; 2006 May; 2(5):244-5. PubMed ID: 16932433
    [No Abstract]   [Full Text] [Related]  

  • 37. Erythropoietin-stimulating agent-resistant vitamin B
    Searcy K; Rainwater S; Jeroudi M; Baliga R
    Pediatr Nephrol; 2021 Feb; 36(2):473-476. PubMed ID: 33156411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iron therapy in chronic kidney disease: Recent changes, benefits and risks.
    Ribeiro S; Belo L; Reis F; Santos-Silva A
    Blood Rev; 2016 Jan; 30(1):65-72. PubMed ID: 26342303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO.
    Mittman N; Sreedhara R; Mushnick R; Chattopadhyay J; Zelmanovic D; Vaseghi M; Avram MM
    Am J Kidney Dis; 1997 Dec; 30(6):912-22. PubMed ID: 9398141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erythropoietin therapy in pre-dialysis patients with chronic renal failure: lack of need for parenteral iron.
    Trivedi HS; Brooks BJ
    Am J Nephrol; 2003; 23(2):78-85. PubMed ID: 12481145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.